NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO's VIZAG FORMULATION FACILITY RECEIVES USFDA APPROVAL28-04-2020
28-04-2020
Natco Pharma gets USFDA nod for its Kothur formulations facility
Drug maker Natco Pharma Ltd has got clearance from the US Food and Drug Administration (USFDA) for its formulations unit.The company has successfull25-04-2020
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO RECEIVES ESTABLISHEMENT INSPECTION REPORT (EIR) FOR KOTHUR'S FORMULATION FACILITY25-04-2020
NATCO PHARMA LTD. - 524816 - RTA Compliance Certificate For The Quarter Ended 31St March, 2020
RTA Compliance certificate for the quarter ended 31st March, 202014-04-2020
NATCO PHARMA LTD. - 524816 - Pcs Certificate For The Half Year Ending 31St March 2020
PCS certificate for the half year ending 31st March, 202014-04-2020
NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer14-04-2020
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Report for the quarter ended 31st March 202014-04-2020
NATCO PHARMA LTD. - 524816 - Shareholding for the Period Ended March 31, 2020
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here07-04-2020
USFDA completes inspection of Natco facility
Natco Pharma Ltd has announced the completion of a pre-approval inspection from the United States Food and Drug Administration (USFDA) for its formul08-03-2020